In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria

被引：11

作者：

Chau Minh Tran ^{[2
]}

Tanaka, Kaori ^{[1
,2
]}

Yamagishi, Yuka ^{[3
]}

Goto, Takatsugu ^{[1
]}

Mikamo, Hiroshige ^{[3
]}

Watanabe, Kunitomo ^{[1
,2
]}

机构：

[1] Gifu Univ, Life Sci Res Ctr, Div Anaerobe Res, Gifu 5011194, Japan

[2] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu 5011194, Japan

[3] Aichi Med Univ, Dept Infect Control & Prevent, Aichi 4801195, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2011年 / 55卷 / 05期

关键词：

STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; CARBAPENEM;

D O I：

10.1128/AAC.01038-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We evaluated the in vitro antianaerobic activity of razupenem (SMP-601, PTZ601), a new parenterally administered carbapenem, against 70 reference strains and 323 clinical isolates. Razupenem exhibited broad-spectrum activity against anaerobes, inhibiting most of the reference strains when used at a concentration of <= 1 mu g/ml. Furthermore, it exhibited strong activity, comparable to those of other carbapenems (meropenem and doripenem), against clinically isolated non-fragilis Bacteroides spp. (MIC(90)s of 2 mu g/ml), with MIC(90) values of 0.06, 0.03, and 0.5 mu g/ml against Prevotella spp., Porphyromonas spp., and Fusobacterium spp., respectively. Clinical isolates of anaerobic Gram-positive cocci, Eggerthella spp., and Clostridium spp. were highly susceptible to razupenem (MIC(90)s, 0.03 to 1 mu g/ml).

引用

页码：2398 / 2402

页数：5

共 10 条

[1]

Clinical and Laboratory Standards Institute, 2007, M11A7 CLIN LAB STAND, pM11

[2] Pharmacodynamics of SMP-601 (PTZ601) against Vancomycin-Resistant Enterococcus faecium and Methicillin-Resistant Staphylococcus aureus in Neutropenic Murine Thigh Infection Models [J].

Eguchi, Ken ;

Kanazawa, Katsunori ;

Eriguchi, Yoshiro ;

Ueda, Yutaka .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3391-3398

[3]

Holdeman L.V., 1977, ANAEROBIC LAB MANUAL, V4th

[4]

Jousimies-Somer HR., 2002, WADSWORTH KTL ANAERO

[5] Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus [J].

Kihara, Rie ;

Yanagihara, Katsunori ;

Morinaga, Yoshitomo ;

Araki, Nobuko ;

Nakamura, Shigeki ;

Seki, Masafumi ;

Izumikawa, Koichi ;

Kakeya, Hiroshi ;

Yamamoto, Yoshihiro ;

Tsukamoto, Kazuhiro ;

Kamihira, Shimeru ;

Kohn, Shigeru .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) :2163-2168

[6] Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms [J].

Livermore, David M. ;

Mushtaq, Shazad ;

Warner, Marina .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :330-335

[7]

Summanen P., 1993, Wadsworth Anaerobic Bacteriology Manual, V5th

[8] In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem [J].

Ueda, Y ;

Kanazawa, K ;

Eguchi, K ;

Takemoto, K ;

Eriguchi, Y ;

Sunagawa, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4185-4196

[9]

YOUNG C, 2007, 17 EUR C CLIN MIRC I

[10]

Young CL, 2007, 47 INT C ANT AG CHEM

← 1 →